Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:80878
Name IDH-wildtype glioblastoma
Definition A glioblastoma that is characterized by high cellularity, high mitotic activity, necrosis or microvascular proliferation and that lacks mutations in IDH genes.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer cell type cancer high grade glioma malignant astrocytoma glioblastoma IDH-wildtype glioblastoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
BRAF V600E Vemurafenib IDH-wildtype glioblastoma predicted - sensitive detail...
BRAF V600E Dabrafenib + Trametinib IDH-wildtype glioblastoma predicted - sensitive detail...
IDH1 wild-type N/A IDH-wildtype glioblastoma not applicable detail...
IDH2 wild-type N/A IDH-wildtype glioblastoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03158389 Phase Ib/II Vismodegib Alectinib Idasanutlin Temsirolimus Atezolizumab Palbociclib APG101 NCT Neuro Master Match - N²M² (NOA-20) (N²M²) Completed DEU 0
NCT04910022 Phase Ib/II NMS-03305293 + Temozolomide Lomustine Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma Recruiting USA | NLD | ITA | CHE 0
NCT04945148 Phase II Metformin + Temozolomide Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide (OPTIMUM) Recruiting ITA | FRA 0
NCT05168423 Phase I CART-EGFR-IL13Ra2 cells CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM Recruiting USA 0
NCT05267106 Phase II Pemigatinib Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DNK | DEU 1
NCT05432375 Phase I Tinostamustine Study of Tinostamustine for Adjuvant Treatment of Glioblastoma Active, not recruiting ESP | CHE 0
NCT05432518 Phase I Olaparib Palbociclib Afatinib Everolimus Dasatinib GBM Personalized Trial Recruiting CAN 0
NCT05463848 Phase II Olaparib + Pembrolizumab + Temozolomide Pembrolizumab Surgical Pembro +/- Olaparib w TMZ for rGBM Recruiting USA 0
NCT05465954 Phase II NT-I7 + Pembrolizumab Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma Recruiting USA 0
NCT05629702 Phase II Nabiximols + Temozolomide Temozolomide ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids (ARISTOCRAT) Recruiting GBR 0
NCT05734560 Phase Ib/II 2141 V-11 + D2C7-IT D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients Recruiting USA 0
NCT05765812 Phase Ib/II Debio 0123 + Temozolomide A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma Recruiting USA | ESP | CHE 0
NCT05879250 Phase II WP1066 WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Recruiting USA 0
NCT05917145 Phase I WSD-0628 Clinical Trial of the ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Recurrent Brain Tumors Recruiting USA 0
NCT05986851 Phase II Azeliragon Azeliragon in MGMT Unmethylated Glioblastoma Active, not recruiting USA 0
NCT06047379 Phase Ib/II NEO212 NEO212 + Regorafenib Carboplatin + NEO212 + Paclitaxel Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NEO212 Ipilimumab + NEO212 NEO212 + Pembrolizumab NEO212 + Nivolumab Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis Recruiting USA 0
NCT06069726 Phase II Atezolizumab A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial (MOAB) Recruiting USA 0
NCT06095375 Phase I Regorafenib + Temozolomide Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients (REGOMA-2) Recruiting ITA 0
NCT06097975 Phase I Ipilimumab + Nivolumab A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma (NEO-GLITIPNI) Not yet recruiting BEL 0
NCT06258018 Phase Ib/II Niraparib + Temozolomide Niraparib and Temozolomide in Patients Glioblastoma (ONC-2022-001) Not yet recruiting ITA 0
NCT06297512 Phase II Doxorubicin + Temozolomide Evaluate the Role of Anthracycline After Radio Therapy in Patients With Glioblastoma (pGBM). Recruiting ITA 0
NCT06410248 Phase I Temozolomide + Triapine Triapine Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma Active, not recruiting USA 0
NCT06504381 Phase Ib/II Toca FC + Vocimagene amiretrorepvec Temozolomide + Toca FC + Vocimagene amiretrorepvec DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma Not yet recruiting USA 0
NCT06552260 Phase I Trigriluzole A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma Not yet recruiting USA 0
NCT06630260 Phase Ib/II Defactinib + RO5126766 + Temozolomide Defactinib + RO5126766 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours (5G-RUBY) Recruiting GBR 0
NCT06632236 Phase I Amivantamab-vmjw 5G-EMERALD: Amivantamab in Malignant Brain Tumours (5G-EMERALD) Recruiting GBR 0
NCT06641908 Phase I M3554 Anti-GD2 ADC M3554 in Advanced Solid Tumors Not yet recruiting USA | FRA | BEL 1
NCT06650605 Phase I 123I-ATT001 Phase 1 Open-label Study of 123I-ATT001 in Subjects with Relapsed Glioblastoma (CITADEL-123) Recruiting GBR 0
NCT06672575 Phase Ib/II Ivonescimab A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma Not yet recruiting USA 0